Karthik Krishnan, MD
Allergy & Immunology · Maryville, TNNPI 1306956586
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 536 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 536 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$1K
- Genentech USA, Inc.$899
- CSL Behring$840
- Sanofi$718
- plus $3K from 25 others
Across 74 payments — averaging $5400.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$219K
- Amgen$77K
- AstraZeneca$65K
- Teva Pharmaceuticals USA, Inc.$39K
What the payments were for
- Consulting fees$250%
- Food & beverage$10,02199%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 139 | $2,053 |
| Regeneron Healthcare Solutions, Inc. | 74 | $1,569 |
| AstraZeneca | 70 | $1,409 |
| Genentech USA, Inc. | 46 | $899 |
| CSL Behring | 38 | $840 |
| Sanofi | 33 | $718 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $572 |
| Grifols USA, LLC | 14 | $291 |
| Kaleo, Inc. | 15 | $269 |
| Boehringer Ingelheim | 14 | $254 |
| Amgen | 11 | $184 |
| Novartis | 8 | $159 |
| Hospira, Inc. | 6 | $122 |
| Shire North American Group Inc | 7 | $115 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $92 |
| Pfizer | 5 | $85 |
| Biocryst US Sales Co., LLC | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Optinose US, Inc. | 3 | $60 |
| Pharming Healthcare, Inc. | 3 | $44 |
| Ionis Pharmaceuticals, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $29 |
| Incyte Corporation | 1 | $28 |
| Cycle Pharmaceuticals Inc | 1 | $27 |
| ADMA Biomanufacturing LLC | 1 | $25 |
| Merck | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Circassia Inc. | 1 | $11 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$10,145 in reported general payments places this provider in the 70th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 12 | $626,321 |
| XolairOmalizumab | 98 | $327,052 |
| HyqviaIgg/Hyaluronidase,recombinant | 60 | $174,948 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 41 | $171,131 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 179 | $137,627 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 35 | $115,532 |
| TezspireTezepelumab-Ekko | 21 | $88,115 |
| Dupixent SyringeDupilumab | 18 | $84,530 |
| FasenraBenralizumab | 11 | $60,916 |
| NucalaMepolizumab | 13 | $44,460 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $30,488 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,863 |
| Epinephrine | 46 | $11,733 |
| Azelastine Hcl | 427 | $11,564 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $11,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Hyqvia | $572 | $801,26972 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $2,053 | $212,574248 claims |
| AstraZenecaTezspire, Fasenra, Breztri Aerosphere, Symbicort | $1,409 | $171,57989 claims |
| CSL BehringHizentra | $840 | $171,13141 claims |
| Grifols USA, LLCGamunex-C | $291 | $115,53235 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $11,73346 claims |
| Boehringer IngelheimSpiriva Respimat | $254 | $10,34120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Maryville
- Tidence PrinceMaryville$269K
- Wilson RobinsonMaryville$7K
- Nicholas KolinskyKnoxville$472K
- Tammy Heinly McCulleyGermantown$165K
- Phillip LiebermanMemphis$131K
- John FahrenholzNashville$124K
- Marc CromieChattanooga$106K
- Reena PatelMemphis$101K
- Jay LiebermanMemphis$81K
- Katherine CahillNashville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.